Gubra A/S (GUBRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gubra A/S (GUBRA) has a cash flow conversion efficiency ratio of 1.899x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr2.31 Billion ≈ $361.00 Million USD) by net assets (Dkr1.22 Billion ≈ $190.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gubra A/S - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Gubra A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Gubra A/S total liabilities for a breakdown of total debt and financial obligations.
Gubra A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gubra A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PPHE Hotel Group Ltd
F:32P
|
0.024x |
|
Zhejiang Huakang Pharmaceutical Co Ltd
SHG:605077
|
N/A |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
-0.002x |
|
Luzerner Kantonalbank AG
LSE:0QNU
|
0.004x |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
0.106x |
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
-0.023x |
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
-0.014x |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
0.028x |
Annual Cash Flow Conversion Efficiency for Gubra A/S (2020–2024)
The table below shows the annual cash flow conversion efficiency of Gubra A/S from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see GUBRA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Dkr450.57 Million ≈ $70.50 Million |
Dkr5.02 Million ≈ $785.26K |
0.011x | +110.81% |
| 2023-12-31 | Dkr479.66 Million ≈ $75.05 Million |
Dkr-49.42 Million ≈ $-7.73 Million |
-0.103x | -145.80% |
| 2022-12-31 | Dkr108.21 Million ≈ $16.93 Million |
Dkr24.34 Million ≈ $3.81 Million |
0.225x | -61.51% |
| 2021-12-31 | Dkr151.46 Million ≈ $23.70 Million |
Dkr88.51 Million ≈ $13.85 Million |
0.584x | +41.74% |
| 2020-12-31 | Dkr80.01 Million ≈ $12.52 Million |
Dkr32.99 Million ≈ $5.16 Million |
0.412x | -- |
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more